ANDSON BIOTECH INC.

ATLANTA, GA · Founded 2021 · CIK 0002017131 · Biotech · Private

An integrated platform for real-time mass spectrometry analysis of cell therapy manufacturing parameters and quality attributes

Grants
$303K
1 award
Sector median: 1
Raised
$8.3M
2 Form D · Oct 2025
12 months since last filing
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$3,600,000
Federal grantDepartment of Health and Human Services · Phase I · A Real-Time Mass Spectrometry Platform for In-Process Monitoring and Cell State Analysis$302,671
Private capital raisedForm D · SEC$4,735,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1462PridCor Therapeutics, LLC—$6.0M
1463BLUESTEM BIOSCIENCES INC—$5.0M
1464Lapix Therapeutics Inc.—$12M
1465ANDSON BIOTECH INC.—$8.3M
1466GC Therapeutics——
1467Endogenex, Inc.—$122M
1468Nob Hill Therapeutics, Inc.—$2.2M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Mason ChilmonczykDirector · Executive Officer
  • Glenn EpsteinDirector
  • Andrei FedorovDirector
  • Jim FilippiniExecutive Officer
  • Thomas O'BrienDirector
  • James RossDirector

Patents

USPTO · 0 granted of 3
  • Systems And Methods For Sample Processingapplication
  • Systems And Methods For Sample Processingapplication
  • Systems And Methods For Sample Processingapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.